Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Harper

Showing results (501-510 of 522) with videos related to

Pageof 53
Sort By:
JCI Insight|April 22, 2021
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancerMichalina Janiszewska, Shayna Stein, Otto Metzger Filho, et al.
Nature Cell Biology|July 3, 2019
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironmentsMichalina Janiszewska, Doris P Tabassum, Zafira Castaño, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2011
Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled studyH Graf, S Fast, F Pacini, et al.
Bioorganic & Medicinal Chemistry Letters|April 14, 1999
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacyM Zhang, D L Bailey, J A Bastian, et al.
Journal of Medicinal Chemistry|February 26, 2000
Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivativesD J Sall, D L Bailey, J A Bastian, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.
Journal of Medicinal Chemistry|June 28, 2019
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic EfficacyMichael M Miller, Jacques Banville, Todd J Friends, et al.
Journal of Medicinal Chemistry|May 17, 2002
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activityT G Murali Dhar, Zhongqi Shen, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2015
Novel phenylalanine derived diamides as Factor XIa inhibitorsLeon M Smith, Michael J Orwat, Zilun Hu, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Steven J Walker, et al.
Pageof 53

Showing results (501-510 of 522) with videos related to

Sort By:
Pageof 53
JCI Insight|April 22, 2021
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancerMichalina Janiszewska, Shayna Stein, Otto Metzger Filho, et al.
Nature Cell Biology|July 3, 2019
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironmentsMichalina Janiszewska, Doris P Tabassum, Zafira Castaño, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2011
Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled studyH Graf, S Fast, F Pacini, et al.
Bioorganic & Medicinal Chemistry Letters|April 14, 1999
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacyM Zhang, D L Bailey, J A Bastian, et al.
Journal of Medicinal Chemistry|February 26, 2000
Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivativesD J Sall, D L Bailey, J A Bastian, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.
Journal of Medicinal Chemistry|June 28, 2019
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic EfficacyMichael M Miller, Jacques Banville, Todd J Friends, et al.
Journal of Medicinal Chemistry|May 17, 2002
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activityT G Murali Dhar, Zhongqi Shen, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2015
Novel phenylalanine derived diamides as Factor XIa inhibitorsLeon M Smith, Michael J Orwat, Zilun Hu, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Steven J Walker, et al.
Pageof 53